Vaxzevria approved in the EU as third dose booster against COVID-19
- Details
- Category: AstraZeneca
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults.
Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine.
Pfizer 'aunches 'An Accord for a Healthier World' to improve health equity for 1.2 billion people living in 45 lower-income countries
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today launched 'An Accord for a Healthier World.' This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world.
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Global Fund to Fight AIDS, Tuberculosis and Malaria are joining forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).
Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine
- Details
- Category: Business
The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.
It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7 million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths.
Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
- Details
- Category: Business
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced they have reached an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Pfizer-BioNTech COVID-19 Vaccine.
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment.
Pfizer to acquire Biohaven Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
More Pharma News ...
- Foundation S: Sanofi's new philanthropic spearhead
- Pfizer shares top-line results from Phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic use
- SK bioscience and GSK's adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study
- Pfizer and Biohaven's VYDURA® (rimegepant) granted first ever marketing authorization by European Commission for both acute treatment of migraine and prophylaxis of episodic migraine
- Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
- Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
- GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn